

해외 바이오의약품 임상 현황 ('24년 3월 4주)

한국바이오의약품협회, 2024.04.02.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2024.03.25.~2024.03.31.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 32건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06158828	Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML	Drug: Rabbit Anti thymocyte globulin Drug: Busulfan Drug: Fludarabine Drug: Thiotepa Drug: Melphalan Biological: TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft Biological: memory-like natural killer cells Biological: IL-2 Drug: Plerixafor Biological: Granulocyte Colony-Stimulating Factor Device: CliniMACS	Washington University School of Medicine The Leukemia and Lymphoma Society Rising Tide Foundation St. Louis Children's Hospital Foundation	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06158828
NCT06149481	Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)	Drug: Retifanlimab Biological: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform Drug: N-803 Drug: SX-682	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06149481
NCT05988632	Intranasal Insulin for Treatment of Alcohol Use Disorder	Drug: Regular Human Insulin then Placebo Drug: Placebo then Regular Human Insulin	Brown University	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05988632
NCT05110742	Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances	Drug: Fludarabine Phosphate Drug: Cyclophosphamide Drug: CAR.5/IL15-transduced CB-NK cells	M.D. Anderson Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05110742
NCT05625633	Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts	Biological: Human Papillomavirus 9-valent Vaccine, Recombinant Other: Normal Saline	Western Institute for Veterans Research University of Utah Merck Sharp & Dohme LLC	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05625633
NCT06340360	A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)	Drug: Rezpegaldesleukin Drug: Placebo	Nektar Therapeutics	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06340360
NCT06311578	A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors	Drug: JNJ-87704916 Drug: Cetrelimab	Johnson & Johnson Enterprise Innovation Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06311578
NCT06247540	Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Biological: Nivolumab Procedure: Positron Emission Tomography Biological: Rituximab Drug: Venetoclax	Northwestern University National Cancer Institute (NCI) Bristol-Myers Squibb AbbVie	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06247540
NCT06194877	A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers	Drug: BGB-3245 Drug: Panitumumab	MapKure, LLC	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06194877

해외 바이오의약품 임상 현황 ('24년 3월 4주)

한국바이오의약품협회, 2024.04.02.

○ 미국 32건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06195891	Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome	Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Dual-Energy Computed Tomography Procedure: Echocardiography Drug: Fludarabine Procedure: Magnetic Resonance Imaging Drug: Melphalan Procedure: Multigated Acquisition Scan Biological: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201 Drug: Tacrolimus Drug: Thiotepa Radiation: Total Marrow and Lymphoid Irradiation	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06195891
NCT06185751	Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma	Biological: WS-CART-CS1 Drug: Lymphodepleting chemotherapy	Washington University School of Medicine Paula C. & Rodger O. Riney Blood Cancer Research	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06185751
NCT06108232	Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma	Drug: Obinutuzumab Drug: CC-99282	M.D. Anderson Cancer Center Bristol-Myers Squibb	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06108232
NCT06083883	Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1	Drug: Fludarabine phosphate Drug: NY-ESO-1 TCR/IL-15 NK Drug: Cyclophosphamide	M.D. Anderson Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06083883
NCT06048250	Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma	Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Computed Tomography Biological: Mezigdomide Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06048250
NCT05629546	Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors	Biological: Memory-like natural killer cells Biological: Relatlimab Biological: Nivolumab	Washington University School of Medicine	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05629546
NCT03988283	Neopeptide-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors	Biological: Personalized neoantigen DNA vaccine Device: Papivax Biotech TDS-IM v2.0 Procedure: Peripheral blood draw	Washington University School of Medicine Children's Discovery Institute	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03988283
NCT06334393	Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults	Biological: VLA1601 Biological: CpG 1018 𐄂 Biological: 3M-052-AF	Valneva Austria GmbH	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06334393
NCT06299163	NM32-2668 in Adult Patients With Selected Advanced Solid Tumors	Biological: NM32-2668	Numab Therapeutics AG	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06299163
NCT06265688	First In Human Study of CX-2051 in Advanced Solid Tumors	Drug: CX-2051	CytomX Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06265688
NCT05911308	Pilot Study of Abequolixron (RGX-104) and Durvalumab in Lung Cancer	Drug: Durvalumab Drug: Carboplatin Drug: Abequolixron Drug: Abraxane Drug: Pemetrexed	UNC Lineberger Comprehensive Cancer Center AstraZeneca Rgenix, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05911308

해외 바이오의약품 임상 현황 ('24년 3월 4주)

한국바이오의약품협회, 2024.04.02.

○ 미국 32건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06096779	A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis	Drug: Atezolizumab Drug: Bevacizumab	Genentech, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06096779
NCT05589896	A First-in-Human Study of HLA-Partially to Fully Matched Allogeneic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies	Other: Ossium HPC Marrow, Bone Marrow Transplant Other: Pre-transplant conditioning - Myeloablative (MAC) Other: Pre-transplant conditioning - Reduced Intensity (RIC) Other: Post-transplant treatment	Ossium Health, Inc. Center for International Blood and Marrow Transplant Research	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05589896
NCT05826015	AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer	Drug: Paclitaxel Drug: Batiraxcept	Washington University School of Medicine National Cancer Institute (NCI) Aravive, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05826015
NCT06242691	Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors	Biological: MK-1200 Drug: Antiemetic	Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06242691
NCT06137183	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)	Drug: Vixarelimab Drug: Placebo	Genentech, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06137183
NCT06265727	A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors	Drug: CRB-701	Corbus Pharmaceuticals Inc. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06265727
NCT06323161	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06323161
NCT06232707	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Drug: Alnuctamab Drug: Pomalidomide Drug: Daratumumab Drug: Elotuzumab Drug: Carfilzomib Drug: Dexamethasone	Celgene	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06232707
NCT06008093	A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients	Drug: Durvalumab Drug: Tremelimumab Drug: Pemetrexed Drug: Pembrolizumab Drug: Carboplatin Drug: Cisplatin	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06008093
NCT06012435	A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer	Drug: sigvotatug vedotin Drug: docetaxel	Seagen Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06012435
NCT05719441	A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission	Biological: VRC07-523LS Biological: PGT121.414.LS Other: Placebo Drug: ART	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05719441
NCT06174987	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Drug: T-DXd	Daiichi Sankyo AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06174987

해외 바이오의약품 임상 현황 ('24년 3월 4주)

한국바이오의약품협회, 2024.04.02.

○ 영국 3건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06232707	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Drug: Alnuctamab Drug: Pomalidomide Drug: Daratumumab Drug: Elotuzumab Drug: Carfilzomib Drug: Dexamethasone	Celgene	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06232707
NCT06265727	A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors	Drug: CRB-701	Corbus Pharmaceuticals Inc. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06265727
NCT06174987	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Drug: T-DXd	Daiichi Sankyo AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06174987

○ 프랑스 2건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06232707	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Drug: Alnuctamab Drug: Pomalidomide Drug: Daratumumab Drug: Elotuzumab Drug: Carfilzomib Drug: Dexamethasone	Celgene	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06232707
NCT06174987	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Drug: T-DXd	Daiichi Sankyo AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06174987

○ 독일 1건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06232707	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Drug: Alnuctamab Drug: Pomalidomide Drug: Daratumumab Drug: Elotuzumab Drug: Carfilzomib Drug: Dexamethasone	Celgene	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06232707

○ 중국 13건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06334367	Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT	Drug: CD25 treatment Drug: low-dose ATG	Wang Xin Shandong Provincial Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06334367
NCT06323369	Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma	Drug: Tislelizumab (neoadjuvant) Drug: Cisplatin (neoadjuvant) Drug: Nab-paclitaxel (neoadjuvant) Procedure: Surgical resection Drug: Cisplatin (adjuvant) Drug: Tislelizumab (adjuvant) Radiation: Radiation Drug: Carboplatin (neoadjuvant) Drug: Carboplatin (adjuvant)	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06323369
NCT06295549	Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	Biological: LUCAR-G39P cells product	The First Affiliated Hospital with Nanjing Medical University Nanjing Legend Biotech Co.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06295549
NCT06280105	A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib	Drug: Cadonilimab+regorafenib	Meng Chao Hepatobiliary Hospital of Fujian Medical University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06280105

해외 바이오의약품 임상 현황 ('24년 3월 4주)

한국바이오의약품협회, 2024.04.02.

○ 중국 13건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06243198	A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants	Drug: Lebrikizumab Drug: Placebo	Eli Lilly and Company	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06243198
NCT06238843	A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or	Drug: irinotecan Drug: IBI343 Drug: paclitaxel	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06238843
NCT06208462	Neoadjuvant Therapy of HAIC (GEMOX) Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors	Drug: Adebrelimab Drug: Lenvatinib Drug: Gemcitabine Drug: Oxaliplatin	The First Affiliated Hospital with Nanjing Medical University Jiangsu Hengrui Pharmaceutical Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06208462
NCT06198465	Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma	Drug: adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil	Xijing Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06198465
NCT06171074	Study of CM310 in Subjects With Seasonal Allergic Rhinitis	Biological: CM310	Keymed Biosciences Co.Ltd	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06171074
NCT06269211	Neoadjuvant Toripalimab for Clinically Stage II-IIIb Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression	Drug: Toripalimab	Ruijin Hospital Guangdong Provincial People's Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06269211
NCT06232707	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Drug: Alnuctamab Drug: Pomalidomide Drug: Daratumumab Drug: Elotuzumab Drug: Carfilzomib Drug: Dexamethasone	Celgene	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06232707
NCT06232161	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06232161
NCT06174987	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Drug: T-DXd	Daiichi Sankyo AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06174987

○ 일본 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06232161	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06232161
NCT06232707	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Drug: Alnuctamab Drug: Pomalidomide Drug: Daratumumab Drug: Elotuzumab Drug: Carfilzomib Drug: Dexamethasone	Celgene	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06232707
NCT06174987	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Drug: T-DXd	Daiichi Sankyo AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06174987